search
Back to results

mHealth Intervention to Support Diabetes Medication Adherence (DIABE-TEXT)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Active
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
DIABE-TEXT
Sponsored by
Fundació d'investigació Sanitària de les Illes Balears
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Diabetes Mellitus, Type 2 focused on measuring diabetes, medication, adherence, glycaemic control, healthy lifestyle, mHealth, SMS

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients registered in the Public Health Service of the Balearic Islands
  • With type 2 diabetes
  • At least one prescription of a glucose-lowering drug
  • With results of HbA1c>8% from 6 months prior to recruitment

Exclusion Criteria:

  • Younger than 18 years old
  • With insulin treatment
  • Participating in another research study
  • Not living in the Balearic Islands at some point during the study development

Sites / Locations

  • Ignacio Ricci-Cabello

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

DIABE-TEXT

Usual care

Arm Description

Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.

Participants allocated to the control group will not receive any intervention apart from usual care.

Outcomes

Primary Outcome Measures

Glycated Hemoglobin (HbA1c) (%)
Extracted from electronic health records
Glycated Hemoglobin (HbA1c) (%)
Extracted from electronic health records
Mean adherence to antidiabetic drugs (%)
Medication possession ratio for antidiabetic drugs
Mean adherence to antidiabetic drugs (%)
Medication possession ratio for antidiabetic drugs

Secondary Outcome Measures

Adherence to oral antidiabetic medication (7 items ad hoc questionnaire)
7 points = adherent; <7 points = non-adherent
Adherence to oral antidiabetic medication (7 items ad hoc questionnaire)
7 points = adherent; <7 points = non-adherent
Health-related quality of life (EQ-5D-5L)
EQ-5D-5L index score
Health-related quality of life (EQ-5D-5L)
EQ-5D-5L index score
Self-efficacy to manage Diabetes (DSES-S)
The score for each item is the number circled. If two consecutive numbers are circled, code the lower number (less self-efficacy). If the numbers are not consecutive, do not score the item. The score for the scale is the mean of the eight items. If more than two items are missing, do not score the scale. Higher number indicates higher self-efficacy.
Self-efficacy to manage Diabetes (DSES-S)
The score for each item is the number circled. If two consecutive numbers are circled, code the lower number (less self-efficacy). If the numbers are not consecutive, do not score the item. The score for the scale is the mean of the eight items. If more than two items are missing, do not score the scale. Higher number indicates higher self-efficacy.

Full Information

First Posted
August 9, 2021
Last Updated
June 29, 2022
Sponsor
Fundació d'investigació Sanitària de les Illes Balears
search

1. Study Identification

Unique Protocol Identification Number
NCT05006872
Brief Title
mHealth Intervention to Support Diabetes Medication Adherence
Acronym
DIABE-TEXT
Official Title
Supporting People With Type 2 Diabetes in Effective Use of Their Medicine Through a System Comprising Mobile Health Technology Integrated With Clinical Care
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 6, 2021 (Actual)
Primary Completion Date
March 31, 2023 (Anticipated)
Study Completion Date
April 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundació d'investigació Sanitària de les Illes Balears

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims at evaluating the effectiveness of an intervention based on the use of a mobile-device based system delivering automated, tailored brief text messages to offer support for medicine use and lifestyle recommendations alongside usual care to people with type 2 diabetes.
Detailed Description
A list of patients registered in primary care centers of the Balearic Islands and potentially meeting the eligibility criteria will be obtained from electronic health records (EHRs). A research assistant will contact the potential participants via phone to invite them to the study and confirm eligibility. All eligible participants will complete informed consent followed by baseline assessment over the phone before randomization. Participants will be randomly allocated using a computer-generated randomization sequence. All participants will continue with their usual diabetes care including all medical visits, tests, and diabetes support programs throughout the study. In addition, the intervention group will receive the text messaging intervention. Control participants will receive usual care only. After twelve months of follow-up, all participants will complete post-intervention assessments via phone interview. Data on glycemic control (HbA1c) at baseline and post-intervention will be extracted from EHRs, as according to the protocol used for primary care providers in the Balearic Islands, patients with poor glycemic control (HbA1c >8% ) must request an HbA1c determination every six months. Results of the most recent determination will be extracted from electronic medical records. For those patients with no recorded HbA1c within the previous four months, the research assistant will contact the primary care center to arrange blood test analyses.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
diabetes, medication, adherence, glycaemic control, healthy lifestyle, mHealth, SMS

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderOutcomes Assessor
Masking Description
Healthcare providers (doctors and nurses from the participants' health centres, do not know if their patients are participating in the study nor the group (intervention vs control) they are. Just if a patient ask them for more information related to the study or text messages, they will know about it. Also, the interviewers that evaluate and register participants data are masked until randomization. After 12 months of follow-up, the interviewers will be masked before post-intervention evaluation. The primary outcome HbA1c is an objective measure and assessors of this outcome will be blinded to treatment allocation.
Allocation
Randomized
Enrollment
741 (Actual)

8. Arms, Groups, and Interventions

Arm Title
DIABE-TEXT
Arm Type
Experimental
Arm Description
Participants allocated to the intervention group will receive text messages in their mobile phones with content about diabetes management, general information about diabetes, medicines, diet and physical activity recommendations and motivational prompts to engage participants in a healthy lifestyle and a good adherence to medication plan. They will also receive reminders for healthcare visits, drug dispensation from the pharmacy and updated results from blood test records.
Arm Title
Usual care
Arm Type
No Intervention
Arm Description
Participants allocated to the control group will not receive any intervention apart from usual care.
Intervention Type
Device
Intervention Name(s)
DIABE-TEXT
Intervention Description
Participants will receive 170 text messages in their mobile phones during twelve months.
Primary Outcome Measure Information:
Title
Glycated Hemoglobin (HbA1c) (%)
Description
Extracted from electronic health records
Time Frame
Baseline
Title
Glycated Hemoglobin (HbA1c) (%)
Description
Extracted from electronic health records
Time Frame
12 months
Title
Mean adherence to antidiabetic drugs (%)
Description
Medication possession ratio for antidiabetic drugs
Time Frame
Baseline
Title
Mean adherence to antidiabetic drugs (%)
Description
Medication possession ratio for antidiabetic drugs
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Adherence to oral antidiabetic medication (7 items ad hoc questionnaire)
Description
7 points = adherent; <7 points = non-adherent
Time Frame
Baseline
Title
Adherence to oral antidiabetic medication (7 items ad hoc questionnaire)
Description
7 points = adherent; <7 points = non-adherent
Time Frame
12 months
Title
Health-related quality of life (EQ-5D-5L)
Description
EQ-5D-5L index score
Time Frame
Baseline
Title
Health-related quality of life (EQ-5D-5L)
Description
EQ-5D-5L index score
Time Frame
12 months
Title
Self-efficacy to manage Diabetes (DSES-S)
Description
The score for each item is the number circled. If two consecutive numbers are circled, code the lower number (less self-efficacy). If the numbers are not consecutive, do not score the item. The score for the scale is the mean of the eight items. If more than two items are missing, do not score the scale. Higher number indicates higher self-efficacy.
Time Frame
Baseline
Title
Self-efficacy to manage Diabetes (DSES-S)
Description
The score for each item is the number circled. If two consecutive numbers are circled, code the lower number (less self-efficacy). If the numbers are not consecutive, do not score the item. The score for the scale is the mean of the eight items. If more than two items are missing, do not score the scale. Higher number indicates higher self-efficacy.
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
14-point Mediterranean diet adherence screener (MEDAS-14)
Description
The score range from 0 to 14. A higher score means a higher adherence to Mediterranean diet. We classified participants as low adherents (≤5), moderate adherents (6-9) or high adherents (≥10).
Time Frame
Baseline
Title
14-point Mediterranean diet adherence screener (MEDAS-14)
Description
The score range from 0 to 14. A higher score means a higher adherence to Mediterranean diet. We classified participants as low adherents (≤5), moderate adherents (6-9) or high adherents (≥10).
Time Frame
12 months
Title
International Physical Activity Questionnaire (IPAQ)
Description
6-items adapted from the short version of the IPAQ by the Public Health System of the Balearic Islands: https:// apps.caib.es/plasalutfront/formularios/ipaq/ipaq.xhtml Result options are: low, moderate or high level of physical activity
Time Frame
Baseline
Title
International Physical Activity Questionnaire (IPAQ)
Description
6-items adapted from the short version of the IPAQ by the Public Health System of the Balearic Islands: https:// apps.caib.es/plasalutfront/formularios/ipaq/ipaq.xhtml Result options are: low, moderate or high level of physical activity
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients registered in the Public Health Service of the Balearic Islands With type 2 diabetes At least one prescription of a glucose-lowering drug With results of HbA1c>8% from 6 months prior to recruitment Exclusion Criteria: Younger than 18 years old With insulin treatment Participating in another research study Not living in the Balearic Islands at some point during the study development
Facility Information:
Facility Name
Ignacio Ricci-Cabello
City
Palma De Mallorca
State/Province
Balearic Islands
ZIP/Postal Code
07002
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

mHealth Intervention to Support Diabetes Medication Adherence

We'll reach out to this number within 24 hrs